Calcium Chloride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Calcium Chloride: From Electrolyte Disorders and Cardiac Arrest to Dyspepsia
One-Sentence Summary
Calcium chloride is a calcium salt originally used for conditions such as potassium deficiency, hypercalcemia-related disorders, nephrocalcinosis, phosphorus metabolism disease and cardiac arrest. The TxGNN model predicts it may be effective for dyspepsia, but no clinical trials and only 1 publication (a formulation study of a different drug) are linked to this prediction. The prediction rests on model output alone, and the available data point toward harm rather than benefit when calcium chloride is taken orally.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Potassium deficiency disease, hypercalcemia disease, nephrocalcinosis, phosphorus metabolism disease, cardiac arrest (from the knowledge graph; no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | Dyspepsia |
| TxGNN Prediction Score | 97.47% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Calcium chloride supplies calcium ions, which take part in muscle contraction, nerve signalling, blood clotting and bone mineral balance. This explains its established roles in electrolyte correction and emergency cardiac care.
Calcium salts, mainly the carbonate, have a long history as antacids. This probably explains the high model score for dyspepsia. However, calcium chloride is a different case. It is highly irritating to the stomach lining, and the linked literature includes a case report of corrosive gastritis after accidental ingestion, and animal studies showing caustic damage to the stomach from oral calcium chloride gel. Calcium chloride is not used orally for dyspepsia.
The link to the original indications is therefore weak. The prediction looks like an association with calcium salts in general, not a sign that calcium chloride would work for dyspepsia.
Other predicted indications fare no better. Calcium-alkali syndrome (rank 2) is caused by excess calcium, so it is a safety signal rather than a therapeutic target. Gastroduodenitis (rank 5) is linked only to a case report of injury caused by the drug. Prothrombin deficiency, bone dysplasia, gastroparesis, hypophosphatemia and oesophageal varices have no supporting trials or literature, and their mechanistic rationale is weak or doubtful.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35319360 | 2022 | Formulation/Preclinical | Current Drug Metabolism | Aceclofenac microspheres in rats to reduce drug-induced gastric ulcers. Calcium-based gelation is only a formulation tool, so this is not evidence for calcium chloride as a treatment. |
The literature linked to the other, lower-ranked predictions (stomach disease, gastroduodenitis, hypophosphatemia) is mostly preclinical, veterinary or a case report of harm, and offers no human evidence of benefit for them.
Singapore Market Information
All 20 licences are valid single-ingredient registrations. No approved indication text is recorded. The 5 listed below are the main ones; the rest include further infusion, dialysis and sealant products.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN06392P | Compound Sodium Lactate Intravenous Infusion BP | Injection | Not recorded |
| SIN05592P | Lactated Ringer's Injection USP | Injection | Not recorded |
| SIN07943P | Haemodialysis Concentrate NKFS-02 (Acid) for Bicarbonate Dialysis | Solution | Not recorded |
| SIN13265P | Balance 1.5% Glucose 1.25 mmol/L Calcium Peritoneal Dialysis Solution | Solution, sterile | Not recorded |
| SIN14707P | Tisseel Fibrin Sealant VH S/D (Frozen) | Solution | Not recorded |
None of the registered products is an oral calcium chloride preparation for gastric use. The registered forms are injectable, dialysis, sealant and other solutions.
Safety Considerations
- Contraindications suggested by the knowledge graph (not taken from label text): hypercalcemia, nephrocalcinosis, nephrolithiasis, kidney disease, anuria, heart disease and coronary artery disease, myocardial infarction, hypertension, peptic ulcer and gastric ulcer, pancreatitis, liver disease, sarcoidosis, and others.
- Local toxicity: The linked literature documents corrosive gastric injury, including stenosis and penetration, after ingestion of calcium chloride.
- Drug Interactions: 100 interactions were found. Major interactions include:
- Ceftriaxone: a calcium-containing solution can cause ceftriaxone-calcium precipitation.
- Digoxin: calcium can increase the risk of cardiac toxicity.
- Moderate interactions include calcium channel blockers (amlodipine, nifedipine, diltiazem, verapamil), thiazide diuretics (hydrochlorothiazide, chlorothiazide, chlorthalidone, metolazone), tetracyclines (doxycycline, tetracycline, minocycline, omadacycline) and topical vitamin D analogues (calcipotriol, calcitriol).
Please refer to the package insert for label warnings and contraindications, since these were not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (L5 for dyspepsia). There are no clinical trials, and the literature shows no benefit in humans and instead documents gastric injury from oral calcium chloride. The other top-ranked predictions are either safety signals (calcium-alkali syndrome, gastroduodenitis) or have no supporting evidence.
To proceed, the following is needed:
- A clear clinical rationale showing why calcium chloride, as opposed to non-corrosive calcium antacids, would suit dyspepsia
- Human safety and efficacy data for any gastrointestinal use
- Package insert warnings and contraindications from HSA
- Mechanism of action data
- A suitable non-irritating oral formulation, since none is registered in Singapore
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.